



US009636378B2

(12) **United States Patent**
Wilson

(10) **Patent No.:** **US 9,636,378 B2**
(45) **Date of Patent:** **May 2, 2017**

(54) **METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY**

(71) Applicant: **Stealth Bio Therapeutics Corp.**
Monaco (MC)

(72) Inventor: **D. Travis Wilson**, Newton, MA (US)

(73) Assignee: **STEALTH BIOTHERAPEUTICS CORP.**, Monaco (MC)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 76 days.

(21) Appl. No.: **14/388,705**

(22) PCT Filed: **Mar. 29, 2013**

(86) PCT No.: **PCT/US2013/034647**

§ 371 (c)(1),

(2) Date: **Sep. 26, 2014**

(87) PCT Pub. No.: **WO2013/149172**

PCT Pub. Date: **Oct. 3, 2013**

(65) **Prior Publication Data**

US 2015/0087595 A1 Mar. 26, 2015

Related U.S. Application Data

(60) Provisional application No. 61/618,428, filed on Mar. 30, 2012.

(51) **Int. Cl.**

A61K 38/07 (2006.01)

A61K 38/08 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 38/07** (2013.01); **A61K 38/08** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,760,001 A 6/1998 Girten et al.
2002/0151465 A1 10/2002 Messing et al.
2009/0253641 A1 10/2009 Neuffer et al.

FOREIGN PATENT DOCUMENTS

CN 101939019 A 1/2011
WO WO-2011/106717 9/2011

OTHER PUBLICATIONS

Shimoyama, et al., "Superior Analgesic Effect of H-Dmt-D-Arg-Phe-Lys-NH₂ ([Dmt1]DALDA), a Multifunctional Opioid Peptide, Compared to Morphine in a Rat Model of Neuropathic Pain," Chemical Biology & Drug Design, (Sep. 3, 2012), vol. 80, Issue 5, pp. 771-774.

International Search Report and Written Opinion received in International Application No. PCT/US2013/034647 mailed Jul. 10, 2013, 9 pages.

Second Office Action received for Chinese Patent Application No. 201380023997.6 issued Feb. 23, 2016, 18 pages—with English translation.

First Office Action received in Chinese Patent Application No. 201380023997.6 issued May 27, 2015, 15 pages.

Joseph, Elizabeth K. et al., "Oxaliplatin Acts on IB4-Positive Nociceptors to Induce and Oxidative Stress-Dependent Acute Painful Peripheral Neuropathy," The Journal of Pain, (May 2008), vol. 9, Issue 5, pp. 463-472.

Extended Search Report received for European Patent Application No. 13769696.9 issued Sep. 21, 2015, 9 pages.

Ferrari, Luiz F. et al., "Role of Drpl, a Key Mitochondrial Fission Protein, in Neuropathic Pain," J of Neuroscience, (Aug. 3, 2011), vol. 31, pp. 11404-11410.

Fidanboyu, Mehmet et al., "Global Inhibition of Reactive Oxygen Species (ROS) Inhibits Paclitaxel-Induced Painful Peripheral Neuropathy," PLOS One, (Sep. 2011), vol. 6, Issue 9, pp. 1-11.

Kim, Hee Kee et al., "Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain," PAIN, (2004), vol. 111, pp. 116-124.

Li, Jianqiao et al., "Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells," Biochem. & Biophys. Res. Commun., (2011), 404, pp. 349-356.

Zhao, Kesheng et al., "Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury," J Biol Chem., (Aug. 2004), vol. 279, No. 33, pp. 34682-34690.

Examination Report issued on Australian Application 2013237827, mailed Dec. 20, 2016.

JPN. J Pharm. Palliat Care Sci, vol. 4, 2011, pp. 1-13 (English translation not available).

Office Action issued on JP Application 2015-503653, mailed Nov. 30, 2016, English translation.

Decision of Rejection issued on Chinese Appl. 201380023997.6, mailed Dec. 26, 2016, English Translation.

Primary Examiner — Christine J Saoud

Assistant Examiner — Jon M Lockard

(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP

(57)

ABSTRACT

The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.

20 Claims, 2 Drawing Sheets